ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 30

Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus

Alaina M. Davis1, T. Brent Graham1, Yuwei Zhu2 and Melissa L. McPheeters3, 1Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, 2Biostatistics, Vanderbilt University, Department of Biostatistics, Nashville, TN, 3Health Policy, Vanderbilt University Medical Center, Department of Health Policy, Nashville, TN

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Compliance, SLE and depression

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, May 20, 2017

Title: Clinical and Therapeutic Poster Breakout II

Session Type: Abstract Submissions

Session Time: 5:15PM-5:45PM

Background/Purpose: The objectives of this study were to estimate prevalence of depression and medication non-adherence, describe demographic and disease characteristics associated with depression and medication non-adherence, and evaluate the association between depression and medication non-adherence among patients with childhood-onset systemic lupus erythematosus (cSLE).

Methods: Participants (n = 51) completed validated screening tools to identify depression and medication non-adherence, Patient Health Questionnaire-9 (PHQ-9) and Medication Adherence Self-report Inventory (MASRI), respectively. Eligibility criteria included a diagnosis of cSLE confirmed using the American College and Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria, presence of prescribed medication for management of SLE for at least 1 month, and ability to complete the consent form and study questionnaires in English. Demographic and disease characteristics for each enrolled participant were obtained via chart abstraction and compared between groups of depression and medication non-adherence. A multivariable linear regression model adjusting for propensity scores was conducted to evaluate the association between depression and medication non-adherence.

Results: The prevalence of a positive depression screen was 58.8% and four patients reported suicidal ideation (13.7%). The prevalence of self-reported medication non-adherence was 19.7%.  There were no statistically significant differences for measured demographic and disease characteristics between patients with a positive vs. negative depression screen. Patients reporting medication non-adherence were more likely to have longer disease duration (2.6 vs. 4.8 years, p = 0.035). As the severity of depression symptoms increased, the degree of medication non-adherence also increased (β = -1.89; p = 0.011). 

Conclusion: The prevalence of depression and medication non-adherence is high in cSLE, and these two factors are directly related.  Prospective, multi-center studies are needed to better characterize the relationship between depression and medication non-adherence to inform development of interventions that address these factors and improve outcomes in cSLE.  

 


Disclosure: A. M. Davis, None; T. B. Graham, None; Y. Zhu, None; M. L. McPheeters, None.

To cite this abstract in AMA style:

Davis AM, Graham TB, Zhu Y, McPheeters ML. Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/cross-sectional-analysis-of-depression-and-medication-non-adherence-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cross-sectional-analysis-of-depression-and-medication-non-adherence-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology